2023 World Conference on Lung Cancer (Posters)-EP08.02. Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC?

EP08.02. Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC? - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the proportion of patients with stage III non-small-cell lung cancer (NSCLC) who are unable to complete concurrent chemoradiotherapy (CRT) and therefore would not be eligible for adjuvant durvalumab, an immunotherapy drug that improves survival in these patients. The study analyzed data from 265 patients who received definitive CRT at a cancer center between 2012 and 2022. Out of these patients, only 7.5% ceased treatment early, while 92.5% completed the full course of radiotherapy as prescribed. Reasons for early cessation included sepsis, thromboembolism, and esophagitis. The study found no significant association between early treatment cessation and potential risk factors such as age and performance status. The results indicate that the majority of appropriately selected and managed patients with stage III NSCLC can tolerate CRT and can access the benefits of adjuvant durvalumab. These findings are reassuring for patients and support the use of multimodality therapy for stage III NSCLC, including both chemoradiotherapy and immunotherapy. The study highlights the importance of completing the full course of CRT to ensure eligibility for adjuvant immunotherapy. Overall, this research provides valuable insights into the feasibility of combining different treatment modalities for stage III NSCLC and the potential impact of early treatment cessation on access to adjuvant therapies.

Asset Subtitle

Michael MacManus

Meta Tag

Speaker Michael MacManus

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

stage III non-small-cell lung cancer

concurrent chemoradiotherapy

adjuvant durvalumab

immunotherapy drug

survival

definitive CRT

early treatment cessation

risk factors

multimodality therapy

adjuvant therapies